ClinicalTrials.gg
CompletedNCT00463385Updated Nov 20, 2019Results posted

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

A Phase 2 interventional study of Pomalidomide and Prednisone in Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia and Myelofibrosis, sponsored by Celgene. Completed at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 1 of them phase 3. Primary Myelofibrosis · Bristol-Myers Squibb.

Enrollment
6th of 10
88 · median 92
Started
2007
the only one that year
Phase 2
3 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 1st registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

1 of the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).

Read the detailed description

Participants received study treatment in the Double Blind Treatment Phase for up to 12 cycles (336 days; 12 cycles of 28 days each). Participants who completed the Double-Blind Treatment Phase were unblinded and, if receiving pomalidomide and determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, could have continued on their current dose of pomalidomide until disease progression. Participants receiving placebo were discontinued from the study.

03

Conditions studied

  • Myelofibrosis With Myeloid Metaplasia
  • Myeloid Metaplasia
  • Myelofibrosis

Keywords

  • Celgene
  • CC-4047
  • Myelofibrosis
  • myelofibrosis with myeloid metaplasia
  • myeloid metaplasia
  • JAK2
  • CC-4047-MMM-001
  • Prednisone
  • Phase II
  • pomalidomide
  • bone marrow histology
  • imids
  • MMM
  • Ashkenazi Jewish Population
  • exposure to Thorotrast
  • exposure to solvents (benzene and toluene)
  • acute megakaryocytic leukemia
  • history of polycythemia vera
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must sign an form
  • Must be >18 years of age
  • Must be diagnosed with myelofibrosis
  • Eligibility is based on local pathology review of bone marrow aspirate and
  • Screening total level \< 10g/dL or transfusion-dependent anemia defined as per International Working Group (IWG) criteria.
  • Must have adequate organ function as demonstrated by the following ≤ 14 days prior to starting study drug:

    • (ALT; SGPT)/aspartate aminotransferase (AST; SGOT) ≤ 3 x (ULN), [unless upon judgment of the treating physician, it is believed to be due to extra-medullary hematopoiesis (EMH)].
    • Total \<3x ULN or Direct Bilirubin \<2 x ULN
    • Serum creatinine ≤ 2.0 mg/dL
    • ≥ 1,000/μL (≥ 1 x 10\^9/L).
    • count ≥ 50,000 /μL (≥ 50 x 10\^9/L).
  • Patients must be willing to receive transfusion of blood products
  • (ECOG) performance status (PS) of 0, 1, or 2 at screening.
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • No active with the exception of controlled prostate cancer, basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
  • Must agree to follow pregnancy precautions as required per the protocol

Exclusion criteria

Exclusion Criteria:

  • Known positive status for (HIV), carrier, or active infection.
  • Previous untoward reaction to (specifically, prednisone) therapy that was severe enough, in the opinion of the treating physician, to preclude study participation.
  • The use of any growth factors, cytotoxic chemotherapeutic agents (e.g. hydroxyurea and anagrelide), corticosteroids, or experimental drug or therapy within a minimum of 28 days of starting CC-4047 and/or lack of recovery from all toxicity from previous therapy to grade 1 or better (e.g. alpha interferon may require 84 days of longer or washout).
  • Prior therapy with CC-4047 or, lenalidomide or thalidomide for Myelofibrosis with myeloid metaplasia (MMM). (Prior prednisone use as a therapy for MMM is allowed, but not within 28 days of starting CC-4047).
  • History of deep vein thrombosis or pulmonary embolism within one year of starting study medication.
  • Any serious medical condition or psychiatric illness that would prevent, (as judged by the treating physician) the subject from signing the form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Pregnant or lactating females
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Prednisone

    Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants were discontinued from the study.

    Drug: Prednisone · Drug: Placebo to pomalidomide

  • Experimental
    Pomalidomide

    Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase. After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.

    Drug: Pomalidomide · Drug: Placebo to prednisone

  • Experimental
    Pomalidomide 2 mg + Prednisone

    Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.

    Drug: Pomalidomide · Drug: Prednisone

  • Experimental
    Pomalidomide 0.5 mg + Prednisone

    Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.

    Drug: Pomalidomide · Drug: Prednisone

Interventions

  • Also known as: CC-4047, Pomalyst

  • Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.

  • DrugPlacebo to pomalidomide

    Matching pomalidomide placebo tablets

  • DrugPlacebo to prednisone

    Matching prednisone placebo tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment

    A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.

    Time frame: Up to 168 days

Secondary outcomes

  1. Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment

    A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.

    Time frame: Up to 336 days

  2. Time to the First Clinical Response

    The time to the first clinical response achieved within 168 days after the first study drug dosing date was calculated for participants who achieved a clinical response as: Start date of the first clinical response - the first study drug date +1. A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable.

    Time frame: Up to 168 days

  3. Duration of First Clinical Response

    For RBC-transfusion-dependent patients, duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the date of the first RBC-transfusion administrated at or more than 56 days after the response started. For patients who did not receive a subsequent transfusion after the response started, the end date of response was censored at the day of last hemoglobin assessment. For RBC-transfusion-independent patients, the duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the earlier of the date of a hemoglobin increase of \< 2.0 g/dL and the date of a RBC transfusion at ≥ 56 days after the response started. For patients whose hemoglobin measurements were always ≥ 2.0 g/dL and never received a RBC transfusion after response started, the end date of the response was censored at the date of last hemoglobin measurement. Kaplan-Meier methodology was used.

    Time frame: Up to 40 months

  4. Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores

    The FACT-An comprises the four subscales of the 27-item FACT-General Scale (FACT-G), Physical Well-being, Social/Family Well-being, Emotion Well-being, Functional Well-Being, and the Additional Concerns Anemia subscale. Questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life. * Physical Well-being consists of 7 questions, the subscale score ranges from 0-28; * Social/Family Well-being consists of 7 questions, the subscale score ranges from 0-28; * Emotion Well-being consists of 6 questions, the subscale score ranges from 0-24; * Functional Well-Being consists of 7 questions, the subscale score ranges from 0-28; * Anemia subscale consists of 20 questions, the subscale score ranges from 0-80; * Total FACT-An score ranges from 0-188.

    Time frame: Baseline and Cycle 6 (168 days).

  5. Change From Baseline in Hemoglobin Concentration for Responders

    Change from Baseline in hemoglobin for participants with a clinical response within the first 6 cycles of treatment.

    Time frame: Baseline, Cycle 6 (168 days)

  6. Change From Baseline in Hemoglobin Concentration for Non-Responders

    Change from Baseline in hemoglobin for participants without a clinical response within the first 6 cycles of treatment.

    Time frame: Baseline, Cycle 6 (168 days)

  7. Change From Baseline in Likert Abdominal Pain Scale

    Participants rated abdominal discomfort or pain over the previous week on a scale from zero to ten, where zero is no discomfort or pain and ten is the worst pain imaginable.

    Time frame: Baseline and Cycle 6 (168 days)

  8. Percentage of Participants With Clinical Response by Baseline JAK2 Assessment

    Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.

    Time frame: Up to 336 days

  9. Number of Participants With Adverse Events (AEs)

    A serious AE (SAE) was defined as any AE which resulted in death or was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or constituted an important medical event (events that may have jeopardized the patient or required intervention to prevent one of the outcomes listed above). The severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) or according to the following scale: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Death. The Investigator determined the relationship between study drug and the occurrence of an AE as "Not Related" or "Related" (since the study was double-blinded, a patient receiving only prednisone could have an AE that was judged as related to pomalidomide, and vice-versa).

    Time frame: From date of the first dose of the study drug until discontinuation or the data cut-off date (up to approximately 45 months).

07

Results

Posted Oct 28, 2013

Participant flow

Participant flow — Overall Study
MilestonePrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Started22222222
Treated22221922
Completed0000
Not completed22222222
Withdrew: Other4364
Withdrew: Adverse event5842
Withdrew: Lack of efficacy6679
Withdrew: Withdrawal by subject3334
Withdrew: Lost to follow-up0001
Withdrew: Death2120
Withdrew: Missing2002
Withdrew: 1 participant received commercial drug0100

Outcome measures

PrimaryPercentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment

A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.

Time frame:
Up to 168 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment
percentage of participantsPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment55.0 (31.53 to 76.94)23.5 (6.81 to 49.90)21.1 (6.05 to 45.57)47.6 (25.71 to 70.22)
Statistical analysis
  • Prednisone vs Pomalidomide 2 mg · Fisher Exact · p = 0.092
  • Prednisone vs Pomalidomide 2 mg + Prednisone · Fisher Exact · p = 0.048
  • Prednisone vs Pomalidomide 0.5 mg + Prednisone · Fisher Exact · p = 0.758
SecondaryPercentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment

A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.

Time frame:
Up to 336 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment
percentage of participantsPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment50.0 (28.22 to 71.78)18.2 (5.19 to 40.28)18.2 (5.19 to 40.28)45.5 (24.39 to 67.79)
SecondaryTime to the First Clinical Response

The time to the first clinical response achieved within 168 days after the first study drug dosing date was calculated for participants who achieved a clinical response as: Start date of the first clinical response - the first study drug date +1. A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable.

Time frame:
Up to 168 days
Reported as:
Median · weeks
Time to the First Clinical Response
weeksPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Time to the First Clinical Response0.3 (0.1 to 15.6)8.0 (2.6 to 17.3)10.1 (0.1 to 20.0)1.2 (0.1 to 16.6)
SecondaryDuration of First Clinical Response

For RBC-transfusion-dependent patients, duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the date of the first RBC-transfusion administrated at or more than 56 days after the response started. For patients who did not receive a subsequent transfusion after the response started, the end date of response was censored at the day of last hemoglobin assessment. For RBC-transfusion-independent patients, the duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the earlier of the date of a hemoglobin increase of \< 2.0 g/dL and the date of a RBC transfusion at ≥ 56 days after the response started. For patients whose hemoglobin measurements were always ≥ 2.0 g/dL and never received a RBC transfusion after response started, the end date of the response was censored at the date of last hemoglobin measurement. Kaplan-Meier methodology was used.

Time frame:
Up to 40 months
Reported as:
Median · months
Duration of First Clinical Response
monthsPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Duration of First Clinical Response3.7 (3.0 to 6.6)NA (4.7 to NA)6.0 (2.3 to 9.8)10.6 (2.8 to 16.1)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores

The FACT-An comprises the four subscales of the 27-item FACT-General Scale (FACT-G), Physical Well-being, Social/Family Well-being, Emotion Well-being, Functional Well-Being, and the Additional Concerns Anemia subscale. Questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life. * Physical Well-being consists of 7 questions, the subscale score ranges from 0-28; * Social/Family Well-being consists of 7 questions, the subscale score ranges from 0-28; * Emotion Well-being consists of 6 questions, the subscale score ranges from 0-24; * Functional Well-Being consists of 7 questions, the subscale score ranges from 0-28; * Anemia subscale consists of 20 questions, the subscale score ranges from 0-80; * Total FACT-An score ranges from 0-188.

Time frame:
Baseline and Cycle 6 (168 days).
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores
units on a scalePrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Physical Well-Being subscale0.6 ± 1.500.4 ± 6.425.3 ± 4.042.3 ± 2.26
Social/Family Well-Being subscale1.9 ± 3.08-1.9 ± 2.591.7 ± 3.790.9 ± 6.84
Emotional Well-Being subscale1.3 ± 3.320.0 ± 4.76-0.3 ± 0.581.7 ± 3.47
Functional Well-Being subscale0.9 ± 4.14-2.1 ± 8.992.7 ± 3.062.5 ± 6.50
Anemia subscale1.2 ± 9.472.3 ± 21.3419.3 ± 18.935.8 ± 8.85
Total FACT-An score2.3 ± 12.421.6 ± 36.5127.3 ± 25.7411.4 ± 13.51
SecondaryChange From Baseline in Hemoglobin Concentration for Responders

Change from Baseline in hemoglobin for participants with a clinical response within the first 6 cycles of treatment.

Time frame:
Baseline, Cycle 6 (168 days)
Reported as:
Median · g/dL
Change From Baseline in Hemoglobin Concentration for Responders
g/dLPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Change From Baseline in Hemoglobin Concentration for Responders1.4 (-0.5 to 4.1)2.0 (0.7 to 3.2)—-0.1 (-1.9 to 3.9)
SecondaryChange From Baseline in Hemoglobin Concentration for Non-Responders

Change from Baseline in hemoglobin for participants without a clinical response within the first 6 cycles of treatment.

Time frame:
Baseline, Cycle 6 (168 days)
Reported as:
Median · g/dL
Change From Baseline in Hemoglobin Concentration for Non-Responders
g/dLPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Change From Baseline in Hemoglobin Concentration for Non-Responders1.2 (-0.2 to 2.7)0.1 (-0.8 to 1.3)-0.8 (-2.0 to 1.9)0.5 (-0.3 to 1.0)
SecondaryChange From Baseline in Likert Abdominal Pain Scale

Participants rated abdominal discomfort or pain over the previous week on a scale from zero to ten, where zero is no discomfort or pain and ten is the worst pain imaginable.

Time frame:
Baseline and Cycle 6 (168 days)
Reported as:
Mean · units on a scale
Change From Baseline in Likert Abdominal Pain Scale
units on a scalePrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Change From Baseline in Likert Abdominal Pain Scale0.3 ± 1.83-1.0 ± 3.110.3 ± 1.15-0.1 ± 1.68
SecondaryPercentage of Participants With Clinical Response by Baseline JAK2 Assessment

Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.

Time frame:
Up to 336 days
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response by Baseline JAK2 Assessment
percentage of participantsPrednisone, Positive JAK2Pomalidomide 2 mg, PositiveJAK2Pomalidomide 2 mg + Prednisone, Positive JAK2Pomalidomide 0.5 mg + Prednisone, Positive JAK2Prednisone, Negative JAK2Pomalidomide 2 mg, Negative JAK2Pomalidomide 2 mg + Prednisone, Negative JAK2Pomalidomide 0.5 mg + Prednisone, Negative JAK2
Percentage of Participants With Clinical Response by Baseline JAK2 Assessment46.227.330.066.750.028.612.525.0
SecondaryNumber of Participants With Adverse Events (AEs)

A serious AE (SAE) was defined as any AE which resulted in death or was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or constituted an important medical event (events that may have jeopardized the patient or required intervention to prevent one of the outcomes listed above). The severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) or according to the following scale: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Death. The Investigator determined the relationship between study drug and the occurrence of an AE as "Not Related" or "Related" (since the study was double-blinded, a patient receiving only prednisone could have an AE that was judged as related to pomalidomide, and vice-versa).

Time frame:
From date of the first dose of the study drug until discontinuation or the data cut-off date (up to approximately 45 months).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
At least one AE20211821
At least one AE related to pomalidomide15171615
At least one AE related to prednisone1010115
At least one Grade 3-4 AE10141315
At least one Grade 3-4 AE related to pomalidomide67116
At least one Grade 3-4 AE related to prednisone5263
At least one SAE610118
At least one SAE related to pomalidomide4683
At least one SAE related to prednisone4353
AE leading to discontinuation of pomalidomide71156
AE leading to discontinuation of prednisone5721
AE leading to a dose reduction of pomalidomide0211
AE leading to a dose interruption of pomalidomide5997
AE leading to a dose interruption of prednisone2863

Adverse events

Collected over From the first dose of the study drug through to 30 days after the last dose; up to the data cut-off date of 18 December 2013; up to 81 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prednisone—6/22 (27.3%)20/22 (90.9%)
Pomalidomide 2 mg—10/22 (45.5%)20/22 (90.9%)
Pomalidomide 2 mg + Prednisone—11/19 (57.9%)17/19 (89.5%)
Pomalidomide 0.5 mg + Prednisone—9/22 (40.9%)21/22 (95.5%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
PneumoniaInfections and infestations1/223/223/192/22
Gastrointestinal HaemorrhageGastrointestinal disorders0/222/221/190/22
AnaemiaBlood and lymphatic system disorders0/221/221/192/22
PyrexiaGeneral disorders0/222/220/190/22
Renal Failure AcuteRenal and urinary disorders0/222/221/190/22
BradycardiaCardiac disorders0/220/221/190/22
Lung Infection PseudomonalInfections and infestations0/220/221/190/22
Respiratory Tract InfectionInfections and infestations0/220/221/190/22
Urinary Tract Infection EnterococcalInfections and infestations0/220/221/190/22
DehydrationMetabolism and nutrition disorders1/220/221/190/22
Most frequent other events
Showing 10 of 114
Most frequent other events
EventPrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + Prednisone
Oedema PeripheralGeneral disorders6/228/2210/1910/22
DiarrhoeaGastrointestinal disorders5/226/227/191/22
CoughRespiratory, thoracic and mediastinal disorders6/226/224/198/22
DizzinessNervous system disorders4/222/226/198/22
RashSkin and subcutaneous tissue disorders1/228/223/193/22
FatigueGeneral disorders6/222/226/197/22
PyrexiaGeneral disorders5/227/224/196/22
DyspnoeaRespiratory, thoracic and mediastinal disorders7/227/223/196/22
Muscle SpasmsMusculoskeletal and connective tissue disorders3/221/226/195/22
EpistaxisRespiratory, thoracic and mediastinal disorders1/222/225/193/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Median66.0 (44.0 to 80.0)68.0 (50.0 to 83.0)67.5 (36.0 to 82.0)69.5 (43.0 to 86.0)67.5 (36.0 to 86.0)
Sex: Female, Male
Sex: Female, Male(Participants)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Female857929
Male1417151359
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
White2122212286
Black00101
Hispanic10001
Janus kinase 2 (JAK2) Mutation
Janus kinase 2 (JAK2) Mutation(participants)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Negative678829
Positive131110943
Missing344516
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Grade 0121161443
Grade 18910633
Grade 2225211
Missing00101
Myelofibrosis with myeloid metaplasia Subtype
Myelofibrosis with myeloid metaplasia Subtype(participants)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Agnogenic Myeloid Metaplasia (AMM)1616161361
Postpolycythemic Myeloid Metaplasia (PPMM)344213
Postthromocythemic Myeloid Metaplasia (PTMM)322714
Time Since Myelofibrosis Diagnosis
Time Since Myelofibrosis Diagnosis(years)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Median1.5 (0.0 to 14.3)0.6 (0.0 to 6.3)1.1 (0.0 to 13.0)1.7 (0.0 to 10.9)1.1 (0.0 to 14.3)
Red Blood Cell (RBC) Transfusion Dependence
Red Blood Cell (RBC) Transfusion Dependence(participants)PrednisonePomalidomide 2 mgPomalidomide 2 mg + PrednisonePomalidomide 0.5 mg + PrednisoneTotal
Yes121091243
No1012131045

1 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • UCLA School of Medicine Hematology/Oncology
    Los Angeles, California 90095, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021-6007, United States
  • New York Presbyterian HospitalWeill Medical College of Cornell University
    New York, New York 10021, United States
  • MD Anderson Cancer Center Leukemia Department
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109-4417, United States
  • Medical University of Vienna, Department of Internal Medicine, Hematology
    Vienna, A-1090, Austria
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • IRCCS Policlinico S. Matteo
    Pavia, 27100, Italy
  • Hematology DepartmentHospital Clinic
    Barcelona, 08036, Spain
  • Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Barosi G, et al. Decrease Of T Regulatory Cells In Patients With Myelofibrosis Receiving Ruxolitinib. Presented at American Society of Hematology 2013, December 7-10, 2013, New Orleans, LA. Abstract No. 4057. Blood, 2013;122(21)
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2007 to primary completion in May 2009, 25 months.

Results were first posted in Oct 2013, 4 years 5 months after primary completion. A results delay was requested in Jan 2011.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 25 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2007
First posted
Apr 20, 2007
StartActual
Apr 1, 2007
Primary completionActual
May 1, 2009
CompletionActual
Dec 31, 2013
Results delay requested
Jan 4, 2011
Results first posted
Oct 28, 2013
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00463385
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 20, 2007
Start date
Apr 1, 2007
Primary completion
May 1, 2009
Completion
Dec 31, 2013
Results posted
Oct 28, 2013
Last update
Nov 20, 2019

Study contacts

Robert Peter Gale, MD, PhD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pomalidomide · Prednisone

Start the discussion